Aardvark Therapeutics, Inc. Common Stock (AARD) - Net Assets
Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) has net assets worth $122.38 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.23 Million) and total liabilities ($10.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aardvark Therapeutics, Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $122.38 Million |
| % of Total Assets | 91.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Aardvark Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Aardvark Therapeutics, Inc. Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. For live valuation and market cap data, see AARD market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-54.64 Million | -57.01% |
| 2023-12-31 | $-34.80 Million | -24.64% |
| 2022-12-31 | $-27.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aardvark Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2779600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $3.68 Million | % |
| Total Equity | $-54.64 Million | 100.00% |
Aardvark Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Aardvark Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Apollo Food Holdings Bhd
KLSE:6432
|
$118.91 Million |
|
Ann Joo Resources Bhd
KLSE:6556
|
$118.92 Million |
|
Rekor Systems Inc
NASDAQ:REKR
|
$119.00 Million |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
$119.01 Million |
|
Eastern Water Resources Development and Management Public Company Limited
F:7ES1
|
$118.69 Million |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
$118.67 Million |
|
Mitrabara Adiperdana PT
JK:MBAP
|
$118.66 Million |
|
Assertio Therapeutics Inc
NASDAQ:ASRT
|
$118.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aardvark Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -34,802,000 to -54,643,000, a change of -19,841,000.
- Net loss of 20,588,000 reduced equity.
- New share issuances of 85,332,000 increased equity.
- Other factors decreased equity by 84,585,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.59 Million | -37.68% |
| Share Issuances | $85.33 Million | +156.16% |
| Other Changes | $-84.58 Million | -154.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aardvark Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-2.87 | $5.46 | x |
| 2023-12-31 | $-2.70 | $5.46 | x |
| 2024-12-31 | $-4.23 | $5.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aardvark Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.77 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.73 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.12 Million |
Industry Comparison
This section compares Aardvark Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $55,880,778
- Average return on equity (ROE) among peers: -137.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $122.38 Million | 0.00% | 0.09x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more